Clinical Trial Update: Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Sacituzumab Govitecan-hziy versus physician's choice in HR+/HER2- metastatic breast cancer completed; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Sacituzumab govitecan-hziy (sacituzumab govitecan-hziy)

Snippet

Sponsor: Gilead Sciences | Conditions: Metastatic Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2024-10-21